Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children
We determined four carnitine constituents (total and free carnitine and short-and long-chain fatty acid carnitine esters) in serum from 471 patients treated for convulsions with phenobarbital, vaiproic acid, phenytoin, and/or carbamazepine. The 471 patients were in eight treatment groups; four were...
Gespeichert in:
Veröffentlicht in: | The Journal of pediatrics 1991-11, Vol.119 (5), p.799-802 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 802 |
---|---|
container_issue | 5 |
container_start_page | 799 |
container_title | The Journal of pediatrics |
container_volume | 119 |
creator | Hug, George McGraw, Catherine A. Bates, Stephen R. Landrigan, Evelyn A. |
description | We determined four carnitine constituents (total and free carnitine and short-and long-chain fatty acid carnitine esters) in serum from 471 patients treated for convulsions with phenobarbital, vaiproic acid, phenytoin, and/or carbamazepine. The 471 patients were in eight treatment groups; four were treated with monotherapy and four with polytherapy. The means of all four carnitine constituents were significantly reduced in all treatment groups (except for free carnitine in four groups). Total carnitine was reduced by 23% to 48%, free carnitine by 9% to 45%, short-chain fatty acid carnitine by 46% to 64%, and long-chain fatty acid carnitine by 6% to 29%. Patient frequency of reduction for total carnitine was 20% of all patients (10% for free carnitine), 23% of patients receiving valproate (9% for free carnitine), 36% of those receiving phenobarbital (21% for free carnitine), 12% of those receiving phenytoin (8% for free carnitine), and 8% of those receiving carbamazepine (1% for free carnitine). Only for phenobarbital was there an inverse correlation between the serum concentration of the drug and that of carnitine concentration. One patient receiving carbamazepine had a 59% reduction in the total and a 65% reduction in the free carnitine concentration and a fivefold increase in long-chain fatty acid carnitine, values similar to those seen in neonatal lethal carnitine palmitoyl transferase II deficiency. It remains to be determined whether a reduction in serum carnitine values in patients receiving anticonvulsant therapy is of clinical consequence, whether the reduction is present in some patients before the start of therapy, when and by what mechanism carnitine levels may become reduced during therapy, and whether the reduction exists in the solid tissues of these patients. |
doi_str_mv | 10.1016/S0022-3476(05)80306-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72459955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347605803063</els_id><sourcerecordid>72459955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-bc54987ea090d087d8e5e2a2b839ccea43ea93282f823f9e8daf17d273bb27c13</originalsourceid><addsrcrecordid>eNqFkVuLFDEQhRtR1tnVn7CQBxGFac2lL8mTyOKqsCB4eQ7VSbUT6U63SXpk_B_-X9Mzw_roUwLnqzrFOUVxzegrRlnz-gulnJeiapsXtH4pqaBNKR4UG0ZVWzZSiIfF5h55XFzG-INSqipKL4oLpiompNoUfz6jXUxykydTTyKGZSQGgnfJeSRm8gZ9CrACkdglOP-dgE8uK_tliPlL0g4DzAfyy6UdmXfopw5C5xIMW7KHYQ6TMwSMs9ujekiT89u8xK5GHYzwG-fVzHlidm6wAf2T4lEPQ8Sn5_eq-Hb77uvNh_Lu0_uPN2_vSlNVLJWdqSslWwSqqKWytRJr5MA7KZQxCJVAUIJL3ksueoXSQs9ay1vRdbw1TFwVz09785E_F4xJjy4aHAbwOC1Rt7yqlarrDNYn0IQpxoC9noMbIRw0o3qtQx_r0GvWmtb6WIcWee76bLB0I9p_U6f8s_7srEM0MPQBvHHxHquFqhreZOzNCcMcxt5h0NE4zN1YF9AkbSf3n0P-AhtNqwk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72459955</pqid></control><display><type>article</type><title>Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Hug, George ; McGraw, Catherine A. ; Bates, Stephen R. ; Landrigan, Evelyn A.</creator><creatorcontrib>Hug, George ; McGraw, Catherine A. ; Bates, Stephen R. ; Landrigan, Evelyn A.</creatorcontrib><description>We determined four carnitine constituents (total and free carnitine and short-and long-chain fatty acid carnitine esters) in serum from 471 patients treated for convulsions with phenobarbital, vaiproic acid, phenytoin, and/or carbamazepine. The 471 patients were in eight treatment groups; four were treated with monotherapy and four with polytherapy. The means of all four carnitine constituents were significantly reduced in all treatment groups (except for free carnitine in four groups). Total carnitine was reduced by 23% to 48%, free carnitine by 9% to 45%, short-chain fatty acid carnitine by 46% to 64%, and long-chain fatty acid carnitine by 6% to 29%. Patient frequency of reduction for total carnitine was 20% of all patients (10% for free carnitine), 23% of patients receiving valproate (9% for free carnitine), 36% of those receiving phenobarbital (21% for free carnitine), 12% of those receiving phenytoin (8% for free carnitine), and 8% of those receiving carbamazepine (1% for free carnitine). Only for phenobarbital was there an inverse correlation between the serum concentration of the drug and that of carnitine concentration. One patient receiving carbamazepine had a 59% reduction in the total and a 65% reduction in the free carnitine concentration and a fivefold increase in long-chain fatty acid carnitine, values similar to those seen in neonatal lethal carnitine palmitoyl transferase II deficiency. It remains to be determined whether a reduction in serum carnitine values in patients receiving anticonvulsant therapy is of clinical consequence, whether the reduction is present in some patients before the start of therapy, when and by what mechanism carnitine levels may become reduced during therapy, and whether the reduction exists in the solid tissues of these patients.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(05)80306-3</identifier><identifier>PMID: 1941389</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Analysis of Variance ; Biological and medical sciences ; Carbamazepine - administration & dosage ; Carbamazepine - therapeutic use ; Carnitine - blood ; Child ; Drug Combinations ; Fatty Acids - blood ; Fatty Acids, Volatile - blood ; Humans ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Phenobarbital - administration & dosage ; Phenobarbital - therapeutic use ; Phenytoin - administration & dosage ; Phenytoin - therapeutic use ; Seizures - drug therapy ; Valproic Acid - administration & dosage ; Valproic Acid - therapeutic use</subject><ispartof>The Journal of pediatrics, 1991-11, Vol.119 (5), p.799-802</ispartof><rights>1991</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-bc54987ea090d087d8e5e2a2b839ccea43ea93282f823f9e8daf17d273bb27c13</citedby><cites>FETCH-LOGICAL-c441t-bc54987ea090d087d8e5e2a2b839ccea43ea93282f823f9e8daf17d273bb27c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-3476(05)80306-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5394626$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1941389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hug, George</creatorcontrib><creatorcontrib>McGraw, Catherine A.</creatorcontrib><creatorcontrib>Bates, Stephen R.</creatorcontrib><creatorcontrib>Landrigan, Evelyn A.</creatorcontrib><title>Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>We determined four carnitine constituents (total and free carnitine and short-and long-chain fatty acid carnitine esters) in serum from 471 patients treated for convulsions with phenobarbital, vaiproic acid, phenytoin, and/or carbamazepine. The 471 patients were in eight treatment groups; four were treated with monotherapy and four with polytherapy. The means of all four carnitine constituents were significantly reduced in all treatment groups (except for free carnitine in four groups). Total carnitine was reduced by 23% to 48%, free carnitine by 9% to 45%, short-chain fatty acid carnitine by 46% to 64%, and long-chain fatty acid carnitine by 6% to 29%. Patient frequency of reduction for total carnitine was 20% of all patients (10% for free carnitine), 23% of patients receiving valproate (9% for free carnitine), 36% of those receiving phenobarbital (21% for free carnitine), 12% of those receiving phenytoin (8% for free carnitine), and 8% of those receiving carbamazepine (1% for free carnitine). Only for phenobarbital was there an inverse correlation between the serum concentration of the drug and that of carnitine concentration. One patient receiving carbamazepine had a 59% reduction in the total and a 65% reduction in the free carnitine concentration and a fivefold increase in long-chain fatty acid carnitine, values similar to those seen in neonatal lethal carnitine palmitoyl transferase II deficiency. It remains to be determined whether a reduction in serum carnitine values in patients receiving anticonvulsant therapy is of clinical consequence, whether the reduction is present in some patients before the start of therapy, when and by what mechanism carnitine levels may become reduced during therapy, and whether the reduction exists in the solid tissues of these patients.</description><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Carbamazepine - administration & dosage</subject><subject>Carbamazepine - therapeutic use</subject><subject>Carnitine - blood</subject><subject>Child</subject><subject>Drug Combinations</subject><subject>Fatty Acids - blood</subject><subject>Fatty Acids, Volatile - blood</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenobarbital - administration & dosage</subject><subject>Phenobarbital - therapeutic use</subject><subject>Phenytoin - administration & dosage</subject><subject>Phenytoin - therapeutic use</subject><subject>Seizures - drug therapy</subject><subject>Valproic Acid - administration & dosage</subject><subject>Valproic Acid - therapeutic use</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVuLFDEQhRtR1tnVn7CQBxGFac2lL8mTyOKqsCB4eQ7VSbUT6U63SXpk_B_-X9Mzw_roUwLnqzrFOUVxzegrRlnz-gulnJeiapsXtH4pqaBNKR4UG0ZVWzZSiIfF5h55XFzG-INSqipKL4oLpiompNoUfz6jXUxykydTTyKGZSQGgnfJeSRm8gZ9CrACkdglOP-dgE8uK_tliPlL0g4DzAfyy6UdmXfopw5C5xIMW7KHYQ6TMwSMs9ujekiT89u8xK5GHYzwG-fVzHlidm6wAf2T4lEPQ8Sn5_eq-Hb77uvNh_Lu0_uPN2_vSlNVLJWdqSslWwSqqKWytRJr5MA7KZQxCJVAUIJL3ksueoXSQs9ay1vRdbw1TFwVz09785E_F4xJjy4aHAbwOC1Rt7yqlarrDNYn0IQpxoC9noMbIRw0o3qtQx_r0GvWmtb6WIcWee76bLB0I9p_U6f8s_7srEM0MPQBvHHxHquFqhreZOzNCcMcxt5h0NE4zN1YF9AkbSf3n0P-AhtNqwk</recordid><startdate>19911101</startdate><enddate>19911101</enddate><creator>Hug, George</creator><creator>McGraw, Catherine A.</creator><creator>Bates, Stephen R.</creator><creator>Landrigan, Evelyn A.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19911101</creationdate><title>Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children</title><author>Hug, George ; McGraw, Catherine A. ; Bates, Stephen R. ; Landrigan, Evelyn A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-bc54987ea090d087d8e5e2a2b839ccea43ea93282f823f9e8daf17d273bb27c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Carbamazepine - administration & dosage</topic><topic>Carbamazepine - therapeutic use</topic><topic>Carnitine - blood</topic><topic>Child</topic><topic>Drug Combinations</topic><topic>Fatty Acids - blood</topic><topic>Fatty Acids, Volatile - blood</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenobarbital - administration & dosage</topic><topic>Phenobarbital - therapeutic use</topic><topic>Phenytoin - administration & dosage</topic><topic>Phenytoin - therapeutic use</topic><topic>Seizures - drug therapy</topic><topic>Valproic Acid - administration & dosage</topic><topic>Valproic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hug, George</creatorcontrib><creatorcontrib>McGraw, Catherine A.</creatorcontrib><creatorcontrib>Bates, Stephen R.</creatorcontrib><creatorcontrib>Landrigan, Evelyn A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hug, George</au><au>McGraw, Catherine A.</au><au>Bates, Stephen R.</au><au>Landrigan, Evelyn A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1991-11-01</date><risdate>1991</risdate><volume>119</volume><issue>5</issue><spage>799</spage><epage>802</epage><pages>799-802</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>We determined four carnitine constituents (total and free carnitine and short-and long-chain fatty acid carnitine esters) in serum from 471 patients treated for convulsions with phenobarbital, vaiproic acid, phenytoin, and/or carbamazepine. The 471 patients were in eight treatment groups; four were treated with monotherapy and four with polytherapy. The means of all four carnitine constituents were significantly reduced in all treatment groups (except for free carnitine in four groups). Total carnitine was reduced by 23% to 48%, free carnitine by 9% to 45%, short-chain fatty acid carnitine by 46% to 64%, and long-chain fatty acid carnitine by 6% to 29%. Patient frequency of reduction for total carnitine was 20% of all patients (10% for free carnitine), 23% of patients receiving valproate (9% for free carnitine), 36% of those receiving phenobarbital (21% for free carnitine), 12% of those receiving phenytoin (8% for free carnitine), and 8% of those receiving carbamazepine (1% for free carnitine). Only for phenobarbital was there an inverse correlation between the serum concentration of the drug and that of carnitine concentration. One patient receiving carbamazepine had a 59% reduction in the total and a 65% reduction in the free carnitine concentration and a fivefold increase in long-chain fatty acid carnitine, values similar to those seen in neonatal lethal carnitine palmitoyl transferase II deficiency. It remains to be determined whether a reduction in serum carnitine values in patients receiving anticonvulsant therapy is of clinical consequence, whether the reduction is present in some patients before the start of therapy, when and by what mechanism carnitine levels may become reduced during therapy, and whether the reduction exists in the solid tissues of these patients.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>1941389</pmid><doi>10.1016/S0022-3476(05)80306-3</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3476 |
ispartof | The Journal of pediatrics, 1991-11, Vol.119 (5), p.799-802 |
issn | 0022-3476 1097-6833 |
language | eng |
recordid | cdi_proquest_miscellaneous_72459955 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Analysis of Variance Biological and medical sciences Carbamazepine - administration & dosage Carbamazepine - therapeutic use Carnitine - blood Child Drug Combinations Fatty Acids - blood Fatty Acids, Volatile - blood Humans Medical sciences Neuropharmacology Pharmacology. Drug treatments Phenobarbital - administration & dosage Phenobarbital - therapeutic use Phenytoin - administration & dosage Phenytoin - therapeutic use Seizures - drug therapy Valproic Acid - administration & dosage Valproic Acid - therapeutic use |
title | Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A38%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduction%20of%20serum%20carnitine%20concentrations%20during%20anticonvulsant%20therapy%20with%20phenobarbital,%20valproic%20acid,%20phenytoin,%20and%20carbamazepine%20in%20children&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Hug,%20George&rft.date=1991-11-01&rft.volume=119&rft.issue=5&rft.spage=799&rft.epage=802&rft.pages=799-802&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/S0022-3476(05)80306-3&rft_dat=%3Cproquest_cross%3E72459955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72459955&rft_id=info:pmid/1941389&rft_els_id=S0022347605803063&rfr_iscdi=true |